ElendiLabs Logo
Back to Articles

Need Regulatory Help? Try Our Platform

Post your regulatory questions or request quotations from verified pharmaceutical consultants worldwide. Get matched with experts who specialize in your market.

Post Market Surveillance

February 20, 2026

Approximately 5 minutes

Slovakia Act No. 362/2011 §141(1)(b): Mandatory Serious Incident Reporting for Medical Devices

Slovakia Act No. 362/2011 §141(1)(b): Mandatory Serious Incident Reporting for Medical Devices

Paragraph 141(1)(b) of Act No. 362/2011 Coll. on Medicinal Products and Medical Devices (as amended) requires economic operators (manufacturers, authorised representatives established in Slovakia, importers, distributors) to immediately report to ŠÚKL any serious incident or field safety corrective action (FSCA) concerning a medical device they have placed on the market. This provision transposes the vigilance obligations of Directive 93/42/EEC (MDD) Article 10 and Annex II and continues to apply to legacy devices during the MDR transitional period (Regulation (EU) 2017/745 Article 120). Source: Act No. 362/2011 Coll. §141(1)(b) (https://www.slov-lex.sk/ezbierky/pravne-predpisy/SK/ZZ/2011/362/#paragraf-141.odsek-1.pismeno-b)

2. Definition of Serious Incident

A serious incident is defined as any malfunction, deterioration in characteristics or performance, or inadequacy in labelling/instructions that:

  • Led to or could have led to death or serious deterioration in health of a patient, user or other person
  • Required or could have required medical or surgical intervention to prevent permanent impairment

Incidents solely due to patient pre-existing condition or user error may be excluded after documented rationale. Source: Act No. 362/2011 Coll. §141(1)(b) cross-referencing MDD Art. 2 & MDR Art. 2(65) (https://www.slov-lex.sk/ezbierky/pravne-predpisy/SK/ZZ/2011/362/#paragraf-141.odsek-1.pismeno-b)

3. Who Must Report and Deadlines

  • Manufacturers / Authorised Representatives: Report without undue delay (immediately) upon awareness
  • Importers / Distributors: Report within 2 working days if they become aware of a serious incident with a device they placed on the market
  • Initial report followed by follow-up reports with root cause analysis, corrective actions and trend data

Healthcare professionals and users are encouraged to report to the manufacturer and/or ŠÚKL. Source: Act No. 362/2011 Coll. §141(1)(b) (https://www.slov-lex.sk/ezbierky/pravne-predpisy/SK/ZZ/2011/362/#paragraf-141.odsek-1.pismeno-b)

4. Required Report Content

The vigilance report to ŠÚKL must include at minimum:

  • Device identification (name, model, UDI, serial/lot/batch)
  • Incident description (date, circumstances, patient outcome)
  • Preliminary risk assessment and suspected cause
  • Actions taken or planned (investigation, FSCA, FSN)
  • Reporter contact details

Reports submitted electronically via ŠÚKL vigilance portal. Source: Act No. 362/2011 Coll. §141(1)(b) & ŠÚKL guidance (https://www.slov-lex.sk/ezbierky/pravne-predpisy/SK/ZZ/2011/362/#paragraf-141.odsek-1.pismeno-b)

5. Field Safety Corrective Actions (FSCA) and FSN

When an FSCA is required (recall, software/field update, modification):

  • Notify ŠÚKL in advance
  • Prepare and distribute Field Safety Notice (FSN) in Slovak to affected users
  • Provide ŠÚKL with proof of dissemination and effectiveness

ŠÚKL may coordinate with other EU authorities via EUDAMED (when operational). Source: Act No. 362/2011 Coll. §141(1)(b) in context of MDR Art. 89 (https://www.slov-lex.sk/ezbierky/pravne-predpisy/SK/ZZ/2011/362/#paragraf-141.odsek-1.pismeno-b)

6. ŠÚKL Role and National Coordination

ŠÚKL:

  • Receives, assesses and registers vigilance reports
  • Requests additional information or corrective measures
  • Coordinates national response and communicates with the economic operator
  • May order urgent measures (supply suspension, recall, etc.)
  • Uploads data to EUDAMED and collaborates with other EU competent authorities

Source: Act No. 362/2011 Coll. §141(1)(b) (https://www.slov-lex.sk/ezbierky/pravne-predpisy/SK/ZZ/2011/362/#paragraf-141.odsek-1.pismeno-b)

7. Transitional Period under MDR

Legacy devices under MDD transitional provisions follow the vigilance requirements transposed in §141(1)(b). New devices comply directly with MDR vigilance rules (Articles 87–89). Manufacturers should prepare for full MDR alignment, including EUDAMED reporting. Source: Act No. 362/2011 Coll. §141(1)(b) (https://www.slov-lex.sk/ezbierky/pravne-predpisy/SK/ZZ/2011/362/#paragraf-141.odsek-1.pismeno-b)

8. Practical Guidance for RA Managers

  • Establish internal vigilance SOP with clear 24/7 escalation path
  • Train staff on serious incident thresholds (death/permanent impairment = immediate)
  • Use ŠÚKL electronic portal for submissions and maintain audit trail
  • Prepare Slovak-language FSN templates in advance
  • Document all ŠÚKL communications and follow-up actions
  • Coordinate global vigilance reporting with Slovak-specific obligations

Source: Act No. 362/2011 Coll. §141(1)(b) (https://www.slov-lex.sk/ezbierky/pravne-predpisy/SK/ZZ/2011/362/#paragraf-141.odsek-1.pismeno-b)

9. Consequences of Non-Compliance

Failure to report under §141(1)(b) may result in:

  • Administrative fines
  • Product withdrawal or recall orders
  • Suspension/revocation of marketing authorisation
  • Potential criminal sanctions in cases causing serious harm

Source: Act No. 362/2011 Coll. enforcement provisions (https://www.slov-lex.sk/ezbierky/pravne-predpisy/SK/ZZ/2011/362/#paragraf-141.odsek-1.pismeno-b)

10. Alignment with Full MDR Vigilance

While §141(1)(b) implements MDD vigilance, full MDR application introduces:

  • Stricter initial reporting timelines (10/2/1 days)
  • Periodic summary reporting for certain devices
  • Mandatory EUDAMED submission
  • Enhanced trend reporting obligations

Manufacturers should harmonise Slovak requirements with MDR to avoid duplication. Source: Act No. 362/2011 Coll. §141(1)(b) (https://www.slov-lex.sk/ezbierky/pravne-predpisy/SK/ZZ/2011/362/#paragraf-141.odsek-1.pismeno-b)

Ask Anything

We'll follow up with you personally.

100% response rate • Reply within 7 business days

Your email will not be published. We'll only use it to notify you when we respond.

Need Expert Guidance?

Contact us at contact@elendilabs.com / +852 4416 5550